Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers

Circosta, Paola;Donini, Chiara;Gallo, Susanna;Giraudo, Lidia;Rotolo, Ramona;Galvagno, Federica;Capellero, Sonia;Aglietta, Massimo;Ferrero, Ivana;Fagioli, Franca;Cignetti, Alessandro;Leuci, Valeria;Sangiolo, Dario
2023-01-01

Abstract

Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.
Sep 26
1
6
AML; CAR; HSC transplantation; cell therapy; cytokine-induced killer lymphocytes
Circosta, Paola; Donini, Chiara; Gallo, Susanna; Giraudo, Lidia; Gammaitoni, Loretta; Rotolo, Ramona; Galvagno, Federica; Capellero, Sonia; Basiricò, Marco; Casucci, Monica; Aglietta, Massimo; Ferrero, Ivana; Fagioli, Franca; Cignetti, Alessandro; Carnevale-Schianca, Fabrizio; Leuci, Valeria; Sangiolo, Dario
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2022 - Circosta et al.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 539.16 kB
Formato Adobe PDF
539.16 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1878042
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact